Shares of Opko Health Inc. (NASDAQ:OPK) have earned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $14.21.
Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday. BidaskClub cut shares of Opko Health from a “sell” rating to a “strong sell” rating in a research report on Friday. Finally, Cantor Fitzgerald set a $20.00 price objective on shares of Opko Health and gave the stock a “buy” rating in a research report on Wednesday, October 25th.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 50,000 shares of the stock in a transaction on Monday, February 5th. The stock was purchased at an average price of $4.14 per share, with a total value of $207,000.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $12,705,457.14. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have acquired a total of 425,000 shares of company stock valued at $1,932,550 in the last ninety days. Company insiders own 40.19% of the company’s stock.
Opko Health (NASDAQ OPK) traded up $0.04 during mid-day trading on Tuesday, reaching $4.17. 3,621,074 shares of the company traded hands, compared to its average volume of 4,641,870. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Opko Health has a 1 year low of $4.01 and a 1 year high of $8.92. The company has a market cap of $2,330.00, a PE ratio of -21.95 and a beta of 1.42.
Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The company had revenue of $263.50 million during the quarter, compared to the consensus estimate of $319.43 million. During the same quarter last year, the firm earned ($0.03) EPS. The business’s revenue for the quarter was down 11.6% on a year-over-year basis. equities research analysts anticipate that Opko Health will post -0.27 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/06/opko-health-inc-opk-receives-consensus-rating-of-hold-from-brokerages.html.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.